title: Long-term discordant xenogeneic (porcine-to-primate) bone marrow engraftment in a monkey treated with porcine-specific growth factors.
abstract: BACKGROUND
  Mixed allogeneic hematopoietic chimerism has previously been reliably achieved and shown to induce tolerance to fully MHC-mismatched allografts in mice and monkeys. However, the establishment of hematopoietic chimerism has been difficult to achieve in the discordant pig-to-primate xenogeneic model.
  
  
  METHODS
  To address this issue, two cynomolgus monkeys were conditioned by whole body irradiation (total dose 300 cGy) 6 and 5 days before the infusion of pig bone marrow (BM). Monkey anti-pig natural antibodies were immunoadsorbed by extracorporeal perfusion of monkey blood through a pig liver, immediately before the intravenous infusion of porcine BM (day 0). Cyclosporine was administered for 4 weeks and 15-deoxyspergualin for 2 weeks. One monkey received recombinant pig cytokines (stem cell factor and interleukin 3) for 2 weeks, whereas the other received only saline as a control.
  
  
  RESULTS
  Both monkeys recovered from pancytopenia within 4 weeks of whole body irradiation. Anti-pig IgM and IgG antibodies were successfully depleted by the liver perfusion but returned to pretreatment levels within 12-14 days. Methylcellulose colony assays at days 180 and 300 revealed that about 2% of the myeloid progenitors in the BM of the cytokine-treated recipient were of pig origin, whereas no chimerism was detected in the BM of the untreated control monkey at similar times. The chimeric animal was less responsive by mixed lymphocyte reaction to pig-specific stimulators than the control monkey and significantly hyporesponsive when compared with a monkey that had rejected a porcine kidney transplant.
  
  
  CONCLUSIONS
  To our knowledge, this is the first report of long-term survival of discordant xenogeneic BM in a primate recipient.
authors.affiliation: Transplantation Biology Research Center, Department of Surgery, Massachusetts General Hospital/Harvard Medical School, Boston 02129, USA.
authors.forename: T
authors.initials: T
authors.lastname: Sablinski
authors.forename: D W
authors.initials: DW
authors.lastname: Emery
authors.forename: R
authors.initials: R
authors.lastname: Monroy
authors.forename: R J
authors.initials: RJ
authors.lastname: Hawley
authors.forename: Y
authors.initials: Y
authors.lastname: Xu
authors.forename: P
authors.initials: P
authors.lastname: Gianello
authors.forename: T
authors.initials: T
authors.lastname: Lorf
authors.forename: T
authors.initials: T
authors.lastname: Kozlowski
authors.forename: M
authors.initials: M
authors.lastname: Bailin
authors.forename: D K
authors.initials: DK
authors.lastname: Cooper
authors.forename: A B
authors.initials: AB
authors.lastname: Cosimi
authors.forename: D H
authors.initials: DH
authors.lastname: Sachs
mesh_terms: D000818:Animals; D000906:Antibodies / Q000032:analysis; D016026:Bone Marrow Transplantation / Q000276:immunology / Q000502:physiology*; D002678:Chimera / Q000502:physiology; D006133:Growth Substances / Q000627:therapeutic use*; D007959:Lymphocyte Culture Test, Mixed; D008252:Macaca fascicularis; D008297:Male; D013045:Species Specificity; D013552:Swine; D013556:Swine, Miniature; D013997:Time Factors; D014183:Transplantation, Heterologous / Q000276:immunology / Q000502:physiology*
chemical_list: D000906:Antibodies; D006133:Growth Substances